TRIAL UPDATE: 12 August 2025 Treating inoperable kidney cancer with Stereotactic Ablative Body Radiotherapy (SABR) is both more effective and less expensive than traditional ablative therapies in Australia, according to a new economic analysis of TROG 15.03/ANZUP 16001 FASTRACK II trial data. The findings of the economic evaluation, published
TRIAL UPDATE: 15 July 2025 The TROG 20.01 CHEST-RT trial is set to add to the evidence about whether radiation therapy could be a safe and useful addition in the management of an aggressive form of lung cancer, as outlined in a newly published paper. Congratulations to trial chairs
LATEST NEWS: 11 JUNE 2025 New findings from a trial into treating a common form of skin cancer – cutaneous squamous cell carcinoma (CSCC) – could be a game-changer for many people at high risk of recurrence of disease. Lead investigator Prof Danny Rischin presented results of primary analysis
5 December 2024: Study shows huge improvement in progression-free survival with adjuvant rituximab containing therapy. Newly published findings of extended follow-up from a TROG Cancer Research trial of radiotherapy plus chemo-immunotherapy in follicular lymphoma (TROG 99.03 – Follicular lymphoma) provide valuable evidence in support of changing the current standard
18 September 2024: We’re thrilled to announce the release of globally significant results from the AGITG TOPGEAR study on which TROG collaborated, providing practice-changing evidence about preoperative chemoradiotherapy for gastric cancer. The findings, announced simultaneously at the European Society for Medical Oncology Congress in Barcelona, Spain and published in
The diagnosis of ductal carcinoma in situ (DCIS) of the breast has increased substantially due to mammographic screening, and now accounts for 25 per cent of screen-detected breast cancer. Over 1,600 women are diagnosed with DCIS in Australia every year. However, unlike invasive breast cancer, there are limited knowledge and experience for
